Adoptive cell transfer immunotherapy for patients with solid epithelial cancers

Steven A Rosenberg; Maria R Parkhurst; Paul F Robbins

doi:10.1016/j.ccell.2023.03.003

Adoptive cell transfer immunotherapy for patients with solid epithelial cancers

Cancer Cell. 2023 Apr 10;41(4):646-648. doi: 10.1016/j.ccell.2023.03.003.

Authors

Steven A Rosenberg¹, Maria R Parkhurst², Paul F Robbins²

Affiliations

¹ Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA. Electronic address: [email protected].
² Surgery Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Abstract

Efforts to apply adoptive cell transfer (ACT) immunotherapy to patients with common epithelial cancers have been stimulated by the demonstration that the majority of these patients contain lymphocytes reactive against the expressed products of their cancer mutations. Early efforts to specifically target these antigens have been promising.

MeSH terms

Antigens, Neoplasm* / genetics
Humans
Immunotherapy
Immunotherapy, Adoptive
Neoplasms* / genetics

Substances

Antigens, Neoplasm

Grants and funding

Z01 BC010984/ImNIH/Intramural NIH HHS/United States